Edwards Lifesciences (EW) Chief Financial Officer Scott B. Ullem sold 4,676 shares on April 9, 2026 at $80.50 per share, for total proceeds of about $376,400. Because this was an open-market sale by the company’s CFO, it tends to draw attention: the CFO is a top executive with close visibility into financial performance, cash flow, and guidance-related processes, even though insiders are required to follow trading rules and pre-arranged plans may be involved. The sale is meaningful mainly for what it signals about insider positioning rather than for its size relative to the company. A roughly $376K transaction is notable at the individual level, but it does not necessarily indicate a change in the company’s outlook. Investors often watch whether sales are isolated or part of a broader pattern across executives. Over the past 30 days, the only listed transaction is this sale by Ullem, suggesting limited reported insider activity in the most recent window. The AI-provided context mentions a separate sale by another executive on April 2, 2026, which—if confirmed in filings—would point to multiple senior leaders trimming holdings around similar dollar amounts, a pattern that can also align with routine diversification or tax planning.